Endemic Burkitt lymphoma (eBL) is primarily found in children in equatorial regions and represents the first historical example of a virus-associated human malignancy. Although Epstein-Barr virus (EBV) infection and MYC translocations are hallmarks of the disease, it is unclear whether other factors may contribute to its development. We performed RNA-Seq on 20 eBL cases from Uganda and showed that the mutational and viral landscape of eBL is more complex than previously reported. First, we found the presence of other herpesviridae family members in 8 cases (40%), in particular human herpesvirus 5 and human herpesvirus 8 and confirmed their presence by immunohistochemistry in the adjacent non-neoplastic tissue. Second, we identified a distinct latency program in EBV involving lytic genes in association with TCF3 activity. Third, by comparing the eBL mutational landscape with published data on sporadic Burkitt lymphoma (sBL), we detected lower frequencies of mutations in MYC, ID3, TCF3 and TP53, and a higher frequency of mutation in ARID1A in eBL samples. Recurrent mutations in two genes not previously associated with eBL were identified in 20% of tumors: RHOA and cyclin F (CCNF). We also observed that polyviral samples showed lower numbers of somatic mutations in common altered genes in comparison to sBL specimens, suggesting dual mechanisms of transformation, mutation versus virus driven in sBL and eBL respectively.
References
[1]
World Health O (2008) Report of the ninth meeting of the WHO Technical Advisory Group on Leprosy Control: Cairo, Egypt, 6–7 March 2008. Lepr Rev 79: 452–470. pmid:19274996
[2]
Ogwang MD, Bhatia K, Biggar RJ, Mbulaiteye SM (2008) Incidence and geographic distribution of endemic Burkitt lymphoma in northern Uganda revisited. Int J Cancer 123: 2658–2663. doi: 10.1002/ijc.23800. pmid:18767045
[3]
van den Bosch C (2012) A Role for RNA Viruses in the Pathogenesis of Burkitt's Lymphoma: The Need for Reappraisal. Advances in hematology 2012: 494758. doi: 10.1155/2012/494758. pmid:22550493
[4]
Thorley-Lawson DA, Hawkins JB, Tracy SI, Shapiro M (2013) The pathogenesis of Epstein-Barr virus persistent infection. Curr Opin Virol 3: 227–232. doi: 10.1016/j.coviro.2013.04.005. pmid:23683686
[5]
Kelly G, Bell A, Rickinson A (2002) Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nature medicine 8: 1098–1104. pmid:12219084 doi: 10.1038/nm758
[6]
Kelly GL, Stylianou J, Rasaiyaah J, Wei W, Thomas W, et al. (2013) Different patterns of Epstein-Barr virus latency in endemic Burkitt lymphoma (BL) lead to distinct variants within the BL-associated gene expression signature. Journal of virology 87: 2882–2894. doi: 10.1128/JVI.03003-12. pmid:23269792
[7]
Kelly GL, Milner AE, Baldwin GS, Bell AI, Rickinson AB (2006) Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proceedings of the National Academy of Sciences of the United States of America 103: 14935–14940. pmid:17001014 doi: 10.1073/pnas.0509988103
[8]
Bell AI, Groves K, Kelly GL, Croom-Carter D, Hui E, et al. (2006) Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. The Journal of general virology 87: 2885–2890. pmid:16963746 doi: 10.1099/vir.0.81906-0
[9]
Niedobitek G, Agathanggelou A, Rowe M, Jones EL, Jones DB, et al. (1995) Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma. Blood 86: 659–665. pmid:7605996
[10]
Arvey A, Ojesina AI, Pedamallu CS, Ballon G, Jung J, et al. (2015) The tumor virus landscape of AIDS-related lymphomas. Blood 125: e14–e22. doi: 10.1182/blood-2014-11-599951. pmid:25827832
[11]
Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, et al. (1982) Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A 79: 7824–7827. pmid:6961453 doi: 10.1073/pnas.79.24.7824
[12]
Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, et al. (1985) The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318: 533–538. pmid:3906410 doi: 10.1038/318533a0
[13]
Dave SS, Fu K, Wright GW, Lam LT, Kluin P, et al. (2006) Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 354: 2431–2442. pmid:16760443 doi: 10.1056/nejmoa055759
[14]
Neri A, Barriga F, Knowles DM, Magrath IT, Dalla-Favera R (1988) Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma. Proc Natl Acad Sci U S A 85: 2748–2752. pmid:2833750 doi: 10.1073/pnas.85.8.2748
[15]
Cario G, Stadt UZ, Reiter A, Welte K, Sykora KW (2000) Variant translocations in sporadic Burkitt's lymphoma detected in fresh tumour material: analysis of three cases. Br J Haematol 110: 537–546. pmid:10997962 doi: 10.1046/j.1365-2141.2000.02241.x
[16]
Sander S, Calado DP, Srinivasan L, Kochert K, Zhang B, et al. (2012) Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell 22: 167–179. doi: 10.1016/j.ccr.2012.06.012. pmid:22897848
[17]
Piccaluga PP, De Falco G, Kustagi M, Gazzola A, Agostinelli C, et al. (2011) Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. Blood 117: 3596–3608. doi: 10.1182/blood-2010-08-301556. pmid:21245480
[18]
Schmitz R, Ceribelli M, Pittaluga S, Wright G, Staudt LM (2014) Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med 4. doi: 10.1101/cshperspect.a014282. pmid:24492847
[19]
Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, et al. (2012) Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490: 116–120. doi: 10.1038/nature11378. pmid:22885699
[20]
Giulino-Roth L, Wang K, MacDonald TY, Mathew S, Tam Y, et al. (2012) Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. Blood 120: 5181–5184. doi: 10.1182/blood-2012-06-437624. pmid:23091298
[21]
Naresh KN, Raphael M, Ayers L, Hurwitz N, Calbi V, et al. (2011) Lymphomas in sub-Saharan Africa—what can we learn and how can we help in improving diagnosis, managing patients and fostering translational research? Br J Haematol 154: 696–703. doi: 10.1111/j.1365-2141.2011.08772.x. pmid:21707579
[22]
Gutierrez MI, Bhatia K, Barriga F, Diez B, Muriel FS, et al. (1992) Molecular epidemiology of Burkitt's lymphoma from South America: differences in breakpoint location and Epstein-Barr virus association from tumors in other world regions. Blood 79: 3261–3266. pmid:1317726
[23]
Kelly GL, Long HM, Stylianou J, Thomas WA, Leese A, et al. (2009) An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link. PLoS pathogens 5: e1000341. doi: 10.1371/journal.ppat.1000341. pmid:19283066
[24]
Tierney RJ, Shannon-Lowe CD, Fitzsimmons L, Bell AI, Rowe M (2015) Unexpected patterns of Epstein-Barr virus transcription revealed by a high throughput PCR array for absolute quantification of viral mRNA. Virology 474: 117–130. doi: 10.1016/j.virol.2014.10.030. pmid:25463610
[25]
Oudejans JJ, van den Brule AJ, Jiwa NM, de Bruin PC, Ossenkoppele GJ, et al. (1995) BHRF1, the Epstein-Barr virus (EBV) homologue of the BCL-2 protooncogene, is transcribed in EBV-associated B-cell lymphomas and in reactive lymphocytes. Blood 86: 1893–1902. pmid:7655018
[26]
Lear AL, Rowe M, Kurilla MG, Lee S, Henderson S, et al. (1992) The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle. J Virol 66: 7461–7468. pmid:1331531
[27]
Vladimir Trifonov LP, Enrico Tiacci, Brunangelo Falini, Raul Rabadan (2013) Statistical Algorithm for Variant Frequency Identification. BMC Systems Biology In Press. doi: 10.1186/1752-0509-7-s2-s2
[28]
Rohde M, Richter J, Schlesner M, Betts MJ, Claviez A, et al. (2014) Recurrent RHOA mutations in pediatric Burkitt lymphoma treated according to the NHL-BFM protocols. Genes Chromosomes Cancer 53: 911–916. doi: 10.1002/gcc.22202. pmid:25044415
[29]
Sengupta S, den Boon JA, Chen IH, Newton MA, Dahl DB, et al. (2006) Genome-wide expression profiling reveals EBV-associated inhibition of MHC class I expression in nasopharyngeal carcinoma. Cancer Res 66: 7999–8006. pmid:16912175 doi: 10.1158/0008-5472.can-05-4399
Bouchard C, Staller P, Eilers M (1998) Control of cell proliferation by Myc. Trends in Cell Biology 8: 202–206. pmid:9695840 doi: 10.1016/s0962-8924(98)01251-3
[32]
Portis T, Longnecker R (2004) Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway. Oncogene 23: 8619–8628. pmid:15361852 doi: 10.1038/sj.onc.1207905
[33]
Scholle F, Bendt KM, Raab-Traub N (2000) Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J Virol 74: 10681–10689. pmid:11044112 doi: 10.1128/jvi.74.22.10681-10689.2000
[34]
Swart R, Ruf IK, Sample J, Longnecker R (2000) Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase/Akt pathway. J Virol 74: 10838–10845. pmid:11044134 doi: 10.1128/jvi.74.22.10838-10845.2000
[35]
Fukuda M, Longnecker R (2004) Latent membrane protein 2A inhibits transforming growth factor-beta 1-induced apoptosis through the phosphatidylinositol 3-kinase/Akt pathway. J Virol 78: 1697–1705. pmid:14747535 doi: 10.1128/jvi.78.4.1697-1705.2004
[36]
Brennan P, Mehl AM, Jones M, Rowe M (2002) Phosphatidylinositol 3-kinase is essential for the proliferation of lymphoblastoid cells. Oncogene 21: 1263–1271. pmid:11850846 doi: 10.1038/sj.onc.1205182
[37]
Hatton OL, Harris-Arnold A, Schaffert S, Krams SM, Martinez OM (2014) The interplay between Epstein-Barr virus and B lymphocytes: implications for infection, immunity, and disease. Immunologic research 58: 268–276. doi: 10.1007/s12026-014-8496-1. pmid:24619311
[38]
Chene A, Donati D, Orem J, Mbidde ER, Kironde F, et al. (2009) Endemic Burkitt's lymphoma as a polymicrobial disease: new insights on the interaction between Plasmodium falciparum and Epstein-Barr virus. Seminars in cancer biology 19: 411–420. doi: 10.1016/j.semcancer.2009.10.002. pmid:19897039
[39]
Moormann AM, Snider CJ, Chelimo K (2011) The company malaria keeps: how co-infection with Epstein-Barr virus leads to endemic Burkitt lymphoma. Current opinion in infectious diseases 24: 435–441. doi: 10.1097/QCO.0b013e328349ac4f. pmid:21885920
[40]
Dolcetti R, Dal Col J, Martorelli D, Carbone A, Klein E (2013) Interplay among viral antigens, cellular pathways and tumor microenvironment in the pathogenesis of EBV-driven lymphomas. Seminars in cancer biology 23: 441–456. doi: 10.1016/j.semcancer.2013.07.005. pmid:23917255
[41]
Biryahwaho B, Dollard SC, Pfeiffer RM, Shebl FM, Munuo S, et al. (2010) Sex and geographic patterns of human herpesvirus 8 infection in a nationally representative population-based sample in Uganda. J Infect Dis 202: 1347–1353. doi: 10.1086/656525. pmid:20863232
[42]
Kenney SC, Mertz JE (2014) Regulation of the latent-lytic switch in Epstein-Barr virus. Semin Cancer Biol 26: 60–68. doi: 10.1016/j.semcancer.2014.01.002. pmid:24457012
[43]
Chene A, Donati D, Guerreiro-Cacais AO, Levitsky V, Chen Q, et al. (2007) A molecular link between malaria and Epstein-Barr virus reactivation. PLoS Pathog 3: e80. pmid:17559303 doi: 10.1371/journal.ppat.0030080
[44]
Lin Z, Wang X, Strong MJ, Concha M, Baddoo M, et al. (2013) Whole-genome sequencing of the Akata and Mutu Epstein-Barr virus strains. J Virol 87: 1172–1182. doi: 10.1128/JVI.02517-12. pmid:23152513
[45]
Fish K, Chen J, Longnecker R (2014) Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma. Blood 123: 530–540. doi: 10.1182/blood-2013-07-517649. pmid:24174629
[46]
Dittmer DP (2014) Not like a wrecking ball: EBV fine-tunes MYC lymphomagenesis. Blood 123: 460–461. doi: 10.1182/blood-2013-11-537076. pmid:24458272
[47]
Sander S, Calado DP, Srinivasan L, Kochert K, Zhang BC, et al. (2012) Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis. Cancer Cell 22: 167–179. doi: 10.1016/j.ccr.2012.06.012. pmid:22897848
[48]
Kenney SC, Mertz JE (2014) Regulation of the latent-lytic switch in Epstein-Barr virus. Seminars in cancer biology 26: 60–68. doi: 10.1016/j.semcancer.2014.01.002. pmid:24457012
[49]
Sivachandran N, Wang X, Frappier L (2012) Functions of the Epstein-Barr virus EBNA1 protein in viral reactivation and lytic infection. Journal of virology 86: 6146–6158. doi: 10.1128/JVI.00013-12. pmid:22491455
[50]
Xue SA, Labrecque LG, Lu QL, Ong SK, Lampert IA, et al. (2002) Promiscuous expression of Epstein-Barr virus genes in Burkitt's lymphoma from the central African country Malawi. International journal of cancer Journal international du cancer 99: 635–643. pmid:12115495 doi: 10.1002/ijc.10372
[51]
Li Y, Webster-Cyriaque J, Tomlinson CC, Yohe M, Kenney S (2004) Fatty acid synthase expression is induced by the Epstein-Barr virus immediate-early protein BRLF1 and is required for lytic viral gene expression. Journal of virology 78: 4197–4206. pmid:15047835 doi: 10.1128/jvi.78.8.4197-4206.2004
[52]
Ambrosio MR, Piccaluga PP, Ponzoni M, Rocca BJ, Malagnino V, et al. (2012) The alteration of lipid metabolism in Burkitt lymphoma identifies a novel marker: adipophilin. PloS one 7: e44315. doi: 10.1371/journal.pone.0044315. pmid:22952953
[53]
Jochum S, Moosmann A, Lang S, Hammerschmidt W, Zeidler R (2012) The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination. PLoS pathogens 8: e1002704. doi: 10.1371/journal.ppat.1002704. pmid:22615564
[54]
Jang BG, Jung EJ, Kim WH (2011) Expression of BamHI-A Rightward Transcripts in Epstein-Barr Virus-Associated Gastric Cancers. Cancer research and treatment: official journal of Korean Cancer Association 43: 250–254. doi: 10.4143/crt.2011.43.4.250
[55]
O'Grady T, Cao S, Strong MJ, Concha M, Wang X, et al. (2014) Global bidirectional transcription of the Epstein-Barr virus genome during reactivation. Journal of virology 88: 1604–1616. doi: 10.1128/JVI.02989-13. pmid:24257595
[56]
Vereide DT, Sugden B (2011) Lymphomas differ in their dependence on Epstein-Barr virus. Blood 117: 1977–1985. doi: 10.1182/blood-2010-05-285791. pmid:21088132
[57]
Shain AH, Giacomini CP, Matsukuma K, Karikari CA, Bashyam MD, et al. (2012) Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Proc Natl Acad Sci U S A 109: E252–259. doi: 10.1073/pnas.1114817109. pmid:22233809
[58]
Trifonov V, Pasqualucci L, Dalla Favera R, Rabadan R (2013) MutComFocal: an integrative approach to identifying recurrent and focal genomic alterations in tumor samples. BMC systems biology 7: 25. doi: 10.1186/1752-0509-7-25. pmid:23531283
[59]
Wang K, Kan J, Yuen ST, Shi ST, Chu KM, et al. (2011) Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nature genetics 43: 1219–1223. doi: 10.1038/ng.982. pmid:22037554
[60]
Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, et al. (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. The New England journal of medicine 363: 1532–1543. doi: 10.1056/NEJMoa1008433. pmid:20942669
[61]
Abe H, Maeda D, Hino R, Otake Y, Isogai M, et al. (2012) ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability. Virchows Arch 461: 367–377. doi: 10.1007/s00428-012-1303-2. pmid:22915242
[62]
Wang K, Kan J, Yuen ST, Shi ST, Chu KM, et al. (2011) Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 43: 1219–1223. doi: 10.1038/ng.982. pmid:22037554
[63]
Gulley ML (2015) Genomic assays for Epstein-Barr virus-positive gastric adenocarcinoma. Exp Mol Med 47: e134. doi: 10.1038/emm.2014.93. pmid:25613731
[64]
Wang K, Yuen ST, Xu J, Lee SP, Yan HH, et al. (2014) Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet 46: 573–582. doi: 10.1038/ng.2983. pmid:24816253
[65]
Palomero T, Couronne L, Khiabanian H, Kim MY, Ambesi-Impiombato A, et al. (2014) Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 46: 166–170. doi: 10.1038/ng.2873. pmid:24413734
[66]
Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, et al. (2014) Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 46: 171–175. doi: 10.1038/ng.2872. pmid:24413737
[67]
Yoo HY, Sung MK, Lee SH, Kim S, Lee H, et al. (2014) A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet 46: 371–375. doi: 10.1038/ng.2916. pmid:24584070
[68]
Kakiuchi M, Nishizawa T, Ueda H, Gotoh K, Tanaka A, et al. (2014) Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet 46: 583–587. doi: 10.1038/ng.2984. pmid:24816255
[69]
D'Angiolella V, Esencay M, Pagano M (2013) A cyclin without cyclin-dependent kinases: cyclin F controls genome stability through ubiquitin-mediated proteolysis. Trends Cell Biol 23: 135–140. doi: 10.1016/j.tcb.2012.10.011. pmid:23182110
[70]
D'Angiolella V, Donato V, Vijayakumar S, Saraf A, Florens L, et al. (2010) SCF(Cyclin F) controls centrosome homeostasis and mitotic fidelity through CP110 degradation. Nature 466: 138–142. doi: 10.1038/nature09140. pmid:20596027
[71]
D'Angiolella V, Donato V, Forrester FM, Jeong YT, Pellacani C, et al. (2012) Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell 149: 1023–1034. doi: 10.1016/j.cell.2012.03.043. pmid:22632967
[72]
Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, et al. (2011) BRAF mutations in hairy-cell leukemia. The New England journal of medicine 364: 2305–2315. doi: 10.1056/NEJMoa1014209. pmid:21663470
[73]
Trifonov V, Pasqualucci L, Tiacci E, Falini B, Rabadan R (2013) SAVI: a statistical algorithm for variant frequency identification. BMC systems biology 7 Suppl 2: S2. doi: 10.1186/1752-0509-7-S2-S2. pmid:24564980
[74]
Love C, Sun Z, Jima D, Li G, Zhang J, et al. (2012) The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 44: 1321–1325. doi: 10.1038/ng.2468. pmid:23143597
[75]
Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E, et al. (2012) Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 44: 1316–1320. doi: 10.1038/ng.2469. pmid:23143595
[76]
Langmead B, Salzberg SL (2012) Fast gapped-read alignment with Bowtie 2. Nat Methods 9: 357–359. doi: 10.1038/nmeth.1923. pmid:22388286
[77]
Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local alignment search tool. J Mol Biol 215: 403–410. pmid:2231712 doi: 10.1016/s0022-2836(05)80360-2
[78]
Morgulis A, Coulouris G, Raytselis Y, Madden TL, Agarwala R, et al. (2008) Database indexing for production MegaBLAST searches. Bioinformatics 24: 1757–1764. doi: 10.1093/bioinformatics/btn322. pmid:18567917
[79]
Wagner GP, Kin K, Lynch VJ (2012) Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples. Theory in Biosciences 131: 281–285. doi: 10.1007/s12064-012-0162-3. pmid:22872506
Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, et al. (2010) Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 28: 511–515. doi: 10.1038/nbt.1621. pmid:20436464
[82]
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545–15550. pmid:16199517 doi: 10.1073/pnas.0506580102
[83]
Pozo F, Tenorio A (1999) Detection and typing of lymphotropic herpesviruses by multiplex polymerase chain reaction. J Virol Methods 79: 9–19. pmid:10328531 doi: 10.1016/s0166-0934(98)00164-5
[84]
Laurentino RV, Lopes IG, Azevedo VN, Machado LF, Moreira MR, et al. (2005) Molecular characterization of human T-cell lymphotropic virus coinfecting human immunodeficiency virus 1 infected patients in the Amazon region of Brazil. Mem Inst Oswaldo Cruz 100: 371–376. pmid:16113884 doi: 10.1590/s0074-02762005000400006
[85]
Pellett PE, Spira TJ, Bagasra O, Boshoff C, Corey L, et al. (1999) Multicenter comparison of PCR assays for detection of human herpesvirus 8 DNA in semen. J Clin Microbiol 37: 1298–1301. pmid:10203474
[86]
Qiu J, Smith P, Leahy L, Thorley-Lawson DA (2015) The Epstein-Barr virus encoded BART miRNAs potentiate tumor growth in vivo. PLoS Pathog 11: e1004561. doi: 10.1371/journal.ppat.1004561. pmid:25590614
[87]
Bell AI, Groves K, Kelly GL, Croom-Carter D, Hui E, et al. (2006) Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. J Gen Virol 87: 2885–2890. pmid:16963746 doi: 10.1099/vir.0.81906-0
